A healthcare platform architect is comparing Claude model tiers for a clinical decision support tool. The tool must process 500-page patient records (notes, labs, imaging reports) and generate differential diagnoses. Accuracy and recall of rare conditions are critical — missing a rare diagnosis has severe patient safety consequences. The platform can tolerate 3–5 second response times. Cost is secondary. Which model strategy is appropriate?
Select an answer to reveal the explanation.
Short Explanation
Here's the deal — when patient safety is the explicit priority and cost is secondary, you use the highest-capability model available. Differential diagnosis on 500-page records needs deep reasoning about rare presentations, drug interactions, and subtle lab patterns. The 3–5 second latency tolerance accommodates that heavier model.
Full Explanation
When patient safety is the explicit priority and cost is explicitly secondary, the appropriate strategy is to use the highest-capability model available, such as Claude Opus or the strongest model offered. Differential diagnosis on 500-page patient records requires sophisticated multi-step reasoning about rare presentations, drug interactions, and subtle lab value patterns — exactly the domain where capability differences between model tiers manifest most acutely. The 3–5 second latency tolerance accommodates the highest-capability model. The Claude Haiku cost-efficiency strategy is inappropriate for this safety-critical context because the statistical rarity of edge cases does not reduce individual patient risk. The Claude Sonnet cost-performance-ratio strategy is the optimum for general applications but not when cost is explicitly secondary to accuracy and recall. The ensemble strategy that averages outputs from all three model tiers is not a valid approach for medical diagnosis because averaging conflicting outputs doesn't improve reliability and introduces its own failure modes when models disagree on safety-critical findings.